FGEN
Price
$7.27
Change
-$0.18 (-2.42%)
Updated
Jul 28, 04:59 PM (EDT)
Capitalization
29.14M
13 days until earnings call
INSM
Price
$101.75
Change
-$2.20 (-2.12%)
Updated
Jul 28, 04:59 PM (EDT)
Capitalization
19.33B
9 days until earnings call
Interact to see
Advertisement

FGEN vs INSM

Header iconFGEN vs INSM Comparison
Open Charts FGEN vs INSMBanner chart's image
FibroGen
Price$7.27
Change-$0.18 (-2.42%)
Volume$200
Capitalization29.14M
Insmed
Price$101.75
Change-$2.20 (-2.12%)
Volume$112.63K
Capitalization19.33B
FGEN vs INSM Comparison Chart in %
Loading...
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FGEN vs. INSM commentary
Jul 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEN is a StrongBuy and INSM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 29, 2025
Stock price -- (FGEN: $7.21 vs. INSM: $101.75)
Brand notoriety: FGEN and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FGEN: 30% vs. INSM: 66%
Market capitalization -- FGEN: $29.14M vs. INSM: $19.33B
FGEN [@Biotechnology] is valued at $29.14M. INSM’s [@Biotechnology] market capitalization is $19.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FGEN’s FA Score shows that 0 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s).

  • FGEN’s FA Score: 0 green, 5 red.
  • INSM’s FA Score: 1 green, 4 red.
According to our system of comparison, INSM is a better buy in the long-term than FGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FGEN’s TA Score shows that 5 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).

  • FGEN’s TA Score: 5 bullish, 5 bearish.
  • INSM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FGEN and INSM are a good buy in the short-term.

Price Growth

FGEN (@Biotechnology) experienced а -4.63% price change this week, while INSM (@Biotechnology) price change was -1.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.28%. For the same industry, the average monthly price growth was +17.90%, and the average quarterly price growth was +45.83%.

Reported Earning Dates

FGEN is expected to report earnings on Aug 11, 2025.

INSM is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Biotechnology (+4.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($19.3B) has a higher market cap than FGEN($29.1M). INSM YTD gains are higher at: 47.378 vs. FGEN (-45.534). FGEN has higher annual earnings (EBITDA): -110.48M vs. INSM (-917.87M). INSM has more cash in the bank: 1.2B vs. FGEN (1.73M). FGEN has less debt than INSM: FGEN (73.4M) vs INSM (1.14B). INSM has higher revenues than FGEN: INSM (381M) vs FGEN (7M).
FGENINSMFGEN / INSM
Capitalization29.1M19.3B0%
EBITDA-110.48M-917.87M12%
Gain YTD-45.53447.378-96%
P/E RatioN/AN/A-
Revenue7M381M2%
Total Cash1.73M1.2B0%
Total Debt73.4M1.14B6%
FUNDAMENTALS RATINGS
FGEN vs INSM: Fundamental Ratings
FGEN
INSM
OUTLOOK RATING
1..100
507
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
10011
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6241
P/E GROWTH RATING
1..100
53100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FGEN's Valuation (93) in the Biotechnology industry is in the same range as INSM (96). This means that FGEN’s stock grew similarly to INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for FGEN (100). This means that INSM’s stock grew significantly faster than FGEN’s over the last 12 months.

INSM's SMR Rating (100) in the Biotechnology industry is in the same range as FGEN (100). This means that INSM’s stock grew similarly to FGEN’s over the last 12 months.

INSM's Price Growth Rating (41) in the Biotechnology industry is in the same range as FGEN (62). This means that INSM’s stock grew similarly to FGEN’s over the last 12 months.

FGEN's P/E Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that FGEN’s stock grew somewhat faster than INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FGENINSM
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
72%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 4 days ago
69%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 11 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
81%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LFAV95.54N/A
N/A
LifeX 2059 Longevity Income ETF
IBTH22.40N/A
-0.02%
iShares iBonds Dec 2027 Term Tr ETF
BFIX25.15-0.03
-0.14%
Build Bond Innovation ETF
BFZ10.39-0.02
-0.19%
BLACKROCK CA Municipal
HERD41.29-0.19
-0.47%
Pacer Cash Cows Fund of Funds ETF

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
-2.12%
THAR - INSM
74%
Closely correlated
-2.28%
CARM - INSM
44%
Loosely correlated
-5.85%
ROIV - INSM
42%
Loosely correlated
-1.73%
CRNX - INSM
41%
Loosely correlated
-0.36%
KRYS - INSM
41%
Loosely correlated
+3.59%
More